Search

Your search keyword '"Solovic, Ivan"' showing total 132 results

Search Constraints

Start Over You searched for: Author "Solovic, Ivan" Remove constraint Author: "Solovic, Ivan"
132 results on '"Solovic, Ivan"'

Search Results

1. Mycobacterium Abscessus – Diagnostic and Therapeutic Frontiers in Infection Management

3. Availability and costs of medicines for the treatment of tuberculosis in Europe

6. Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe

7. Availability and costs of medicines for the treatment of tuberculosis in Europe

9. Infection control, genetic assessment of drug resistance and drug susceptibility testing in the current management of multidrug/extensively-resistant tuberculosis (M/XDR-TB) in Europe: A tuberculosis network European Trialsgroup (TBNET) study

12. Tuberculosis incidence in foreign-born people residing in European countries in 2020

13. Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis

15. Screening for Tuberculosis in Migrants: A Survey by the Global Tuberculosis Network

17. Risk Assessment of Tuberculosis in Contacts by IFN-γ Release Assays: A Tuberculosis Network European Trials Group Study

18. Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort

19. Screening for tuberculosis in migrants: a survey by the global tuberculosis network

20. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study

22. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study

23. Isoniazid (INH) mono-resistance and tuberculosis (TB) treatment success: analysis of European surveillance data, 2002 to 2014

24. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report

25. National advisory services for multidrug-resistant tuberculosis (MDRTB) in Europe: an ERS-TBnet survey

26. Isoniazid (INH) mono-resistance and tuberculosis (TB) treatment success: analysis of European surveillance data, 2002 to 2014

27. Guidance for programmatic management of latent tuberculosis infection in the European Union/European Economic Area

28. Migration, TB control and elimination: Whom to screen and treat

29. Burden and Characteristics of the Comorbidity Tuberculosis—Diabetes in Europe: TBnet Prevalence Survey and Case-Control Study

30. Isoniazid mono-resistance negatively affects tuberculosis treatment outcomes in Europe

31. ERS/ECDC Statement: European Union standards for tuberculosis care, 2017 update

33. Infection control, genetic assessment of drug resistance and drug susceptibility testing in the current management of multidrug/extensively-resistant tuberculosis (M/XDR-TB) in Europe: A tuberculosis network European Trialsgroup (TBNET) study

34. Standard operating procedures for tuberculosis care

35. FATE: the new partnership to Fight Against TB in Central and Eastern Europe

37. Risk Assessment of Tuberculosis in Contacts by Interferon-γ Release Assays (IGRAs). A TBNET Study

38. Faster for less: The new 'shorter' regimen for multidrug-resistant tuberculosis

39. Comparison of effectiveness and safety of imipenem/clavulanate-versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB

40. Effectiveness and safety of meropenem/ clavulanate-containing regimens in the treatment of MDR- and XDR-TB

41. Pregnancy in patients with tuberculosis: a TBNET cross-sectional survey

42. Effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of multidrug resistant tuberculosis

43. Faster for less: the new “shorter” regimen for multidrug-resistant tuberculosis

44. Socio-demographic and clinical characteristics of patients with tuberculosis and diabetes in European countries. A TB-net study

45. Tuberculosis care among refugees arriving in Europe: a ERS/WHO Europe Region survey of current practices

47. Comparison of effectiveness and safety of imipenem/clavulanate-versusmeropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB

48. Call for urgent actions to ensure access to early diagnosis and care of tuberculosis among refugees

49. Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB

50. Towards tuberculosis elimination: an action framework for low-incidence countries

Catalog

Books, media, physical & digital resources